Female Pattern Hair Loss vs. Telogen Effluvium: Key Differences

Why the Distinction Matters

Female pattern hair loss (FPHL) and telogen effluvium (TE) account for the majority of hair loss presentations in women. Both cause diffuse thinning and increased shedding, and both can occur in the same patient simultaneously — which is one reason they are so often confused. Getting the diagnosis right matters because the conditions have fundamentally different prognoses and treatments:

• Telogen effluvium is usually self-limiting. Address the trigger, support the body, and hair typically recovers over 6–12 months.
• FPHL is permanent and progressive without treatment. Early diagnosis and starting minoxidil or anti-androgen therapy are critical — the longer treatment is delayed, the more follicular atrophy occurs.

Misidentifying FPHL as TE leads women to "wait and see" for years while irreversible miniaturisation progresses. Misidentifying TE as FPHL causes unnecessary anxiety and inappropriate long-term pharmaceutical treatment for a self-resolving condition.

Head-to-Head Comparison

Understanding Telogen Effluvium

The Normal Hair Cycle and What TE Disrupts

In a healthy scalp, approximately 85–90% of hairs are in the anagen (active growth) phase at any given time, 1–2% in the catagen (transition) phase, and 10–15% in telogen (resting and eventual shedding). Normal daily shedding is 50–100 hairs.

Telogen effluvium occurs when a significant bodily stressor — anything the body interprets as a threat — prematurely shifts a larger proportion of actively growing follicles into the resting phase. The body, in evolutionary terms, prioritises survival over hair growth. Two to four months later, when those resting hairs reach the end of their telogen phase and shed simultaneously, the patient notices a sudden dramatic increase in hair fall.

This 2–4 month delay is the single most important diagnostic clue. The patient typically presents saying "my hair started falling out badly in April," and the dermatologist looks for a stressor in December through February.

Common TE Triggers

• Childbirth (postpartum TE): The most common cause. During pregnancy, elevated estrogen prolongs anagen and reduces normal shedding. After delivery, estrogen drops sharply and the synchronised release of held-back telogen hairs causes shedding that typically peaks at 3–4 months postpartum.
• Severe illness or high fever: COVID-19, influenza, dengue fever, and other systemic illnesses are associated with TE 2–4 months after the acute illness.
• Major surgery or hospitalisation: Physiological stress of surgery and anaesthesia can trigger TE.
• Significant weight loss or crash dieting: Caloric restriction and protein deficiency are potent TE triggers — a common occurrence after bariatric surgery or restrictive eating.
• Iron deficiency anemia: One of the most common and correctable causes. Low ferritin (below 30–40 μg/L) impairs the anagen phase and can cause or sustain TE even without frank anemia.
• Thyroid disorders: Both hypothyroidism and hyperthyroidism cause diffuse telogen shedding.
• Severe psychological stress: Extreme emotional distress can trigger TE via cortisol-mediated pathways, though this is a weaker trigger than physical stressors.
• Medications: Beta-blockers, anticoagulants, isotretinoin, retinoids, and some antidepressants are associated with TE.
• Stopping hormonal contraception: The withdrawal of synthetic estrogen from combined oral contraceptives can trigger a brief TE several months after stopping.

Acute vs. Chronic TE

• Acute TE: Defined as active shedding for fewer than 6 months. Most cases of TE are acute and resolve spontaneously once the triggering factor resolves.
• Chronic TE (CTE): Shedding persisting beyond 6 months with no identifiable or correctable trigger. CTE is a frustrating, poorly understood condition that can persist for years. It is distinguished from FPHL by hair wash tests and dermoscopy — CTE shows heavy diffuse shedding without the follicular miniaturisation characteristic of FPHL.

Understanding Female Pattern Hair Loss Recap

FPHL is covered comprehensively in the Female Pattern Hair Loss Guide. The core distinction for this comparison:

• FPHL is a lifelong, genetically determined process that begins after puberty and progresses unless treated
• It reflects follicular miniaturisation — terminal hairs progressively replaced by vellus-like fibers — not a shift in the hair cycle stage
• The crown and central scalp are specifically affected because those follicles have the highest density of androgen receptors
• The frontal hairline is typically preserved
• There is no acute trigger and no spontaneous recovery

How to Tell Them Apart: Clinical Diagnostic Tools

1. Clinical History

The single most valuable diagnostic step is a detailed history, often conducted before any physical examination:

Clues pointing toward TE:

• "My hair started falling out suddenly [3–5 months ago]"
• A specific event 2–4 months prior: delivery, surgery, major illness, dramatic weight loss, extreme stress
• Previous normal hair density with no long-standing thinning concern
• Heavy generalised shedding — finding hair everywhere, not concentrated on the crown

Clues pointing toward FPHL:

• "My part has been getting wider for years" or "I've been noticing more scalp on top"
• Progressive insidious change without a clear triggering event
• Family history of hair thinning (maternal or paternal side)
• Hair loss that started in the 20s–30s or accelerated at menopause

2. Physical Examination and the Hair Pull Test

The hair pull test is performed by grasping 40–60 hairs between thumb and forefinger and applying gentle, firm traction:

• Positive in active TE: More than 6 telogen hairs extracted across multiple scalp zones (crown, temporal, occipital). The test is positive across the whole scalp.
• Weakly positive in FPHL: Fewer extracted telogen hairs, and only in the affected zones (crown); the occipital scalp pull test is typically negative or borderline.
• Negative in both (when TE has resolved or FPHL is stable): A normal pull test does not exclude either diagnosis.

In one study, a positive pull test was present in 48.8% of TE cases but only 7% of FPHL cases — a meaningful difference in the clinical context.

3. Dermoscopy (Trichoscopy)

Dermoscopy of the scalp at 20–70× magnification is the most practical tool for distinguishing FPHL from TE in a clinical setting:

FPHL dermoscopy findings:

• Hair shaft diameter variability — greater than 20% of examined hairs showing significant calibre differences (the key marker)
• Increased vellus hairs — fine, short, lightly pigmented hairs in affected zones
• Peripilar sign (yellowish-brown perifollicular halo) in some cases
• Decreased follicular unit density in the central compared to the occipital scalp

TE dermoscopy findings:

• Largely uniform hair shaft diameter — minimal calibre variability (no miniaturisation)
• Increased empty follicular openings and upright regrowing hairs (short, tapering new-growth hairs visible after shedding)
• No increase in vellus hairs
• Hair density reduced globally without a central-to-occipital gradient

4. The Hair Wash Test

A validated non-invasive clinical test: the patient abstains from washing hair for 5 days, then shampoos and collects all shed hairs. Hair shafts are divided into short (<3 cm) and long (>3 cm):

• CTE pattern: Mean shed count is high (~438 hairs); fewer than 10% are short
• FPHL pattern: Lower mean count (~215 hairs); a higher proportion of short miniaturised hairs

This test can differentiate chronic TE from FPHL without requiring a scalp biopsy.

5. Blood Tests

Both conditions can be exacerbated by the same systemic factors — making blood tests useful in either context:

• Ferritin: Low ferritin prolongs and perpetuates TE; it also exacerbates FPHL. Target >30–40 μg/L for hair cycle support
• TSH: Thyroid dysfunction causes TE and can worsen FPHL
• Free testosterone, DHEAS: Elevated in hyperandrogenism; relevant to FPHL differential
• Full blood count: Anemia assessment

6. Scalp Biopsy

Scalp biopsy is the definitive tool when dermoscopy and clinical assessment are inconclusive. Horizontal sectioning shows:

• FPHL: Reduced terminal-to-vellus hair ratio (<4:1 in affected scalp); increased miniaturised follicles
• TE: Preserved terminal-to-vellus ratio (>8:1 or normal); increased telogen phase follicles without miniaturisation
• Combined picture (4:1–8:1 ratio): Suggests TE overlying FPHL — the most common diagnostically challenging scenario

When Both Conditions Co-Exist

The most common and diagnostically challenging scenario is FPHL and TE occurring simultaneously in the same patient. This co-occurrence is not coincidental — it is mechanistically plausible:

1. A woman has subclinical FPHL (low-grade miniaturisation not yet clinically apparent)
2. A major stressor (childbirth, illness, rapid weight loss) triggers TE
3. The TE shedding is now far more severe than it would be in a woman without underlying FPHL
4. After the TE resolves, the remaining hair density is lower than before — revealing the underlying FPHL that was previously masked

In this scenario, treating only TE and waiting for recovery is insufficient. The patient will notice that hair does not return to its prior density — because the FPHL was progressing underneath. Identifying and treating both conditions simultaneously produces the best outcome.

Treatment Differences

Treating Telogen Effluvium

• Identify and address the trigger: Correct iron deficiency (ferritin >40 μg/L target in active TE), treat thyroid dysfunction, ensure adequate protein intake (minimum 1.0–1.2 g/kg/day), adjust medications where possible
• Support recovery: A diet rich in protein, iron, zinc, and B vitamins supports follicular re-entry into anagen
• Minoxidil (optional): Topical minoxidil can be used in TE to potentially accelerate the transition of resting follicles back into anagen, and is particularly indicated when TE overlies FPHL
• Patience: Shedding typically peaks 3–6 months after the trigger and resolves spontaneously by 6–12 months. Some shedding is actually evidence of recovery — the new anagen hairs pushing out resting telogen hairs

Treating FPHL

• Topical minoxidil (FDA-approved first-line): Must be continued indefinitely
• Oral minoxidil (off-label): Growing evidence base; endorsed by 2025 international consensus
• Spironolactone (off-label): Effective anti-androgen option for premenopausal women
• Finasteride 2.5–5 mg (off-label): For postmenopausal women or premenopausal women with reliable contraception
• No spontaneous recovery: The chronic nature of FPHL means that watchful waiting is not a treatment plan

When to See a Dermatologist

You should see a dermatologist rather than attempting to self-diagnose if:

• Hair loss is significant, rapid, or distressing
• You cannot identify a clear trigger for your shedding 2–4 months prior
• Hair loss has continued beyond 6 months without clear improvement
• The thinning is concentrated on the crown or top of the scalp (rather than diffuse)
• You notice your part line widening over time
• You have signs of possible hyperandrogenism (irregular periods, acne, hirsutism)
• Your hair has not returned to previous density after a known TE trigger resolved

A dermatologist can perform dermoscopy, targeted blood tests, and — if needed — scalp biopsy to determine precisely which condition (or both) is present, and tailor treatment accordingly.